The MONOFAST surgical suture is indicated for the retention in contact or for the filling of soft tissues excluding cardiovascular and central nervous system tissues.

Furthermore, its use is not indicated in ophthalmological and microsurgical procedures.Implantation of the synthetic absorbable surgical suture MONOFAST initially causes a minimal local tissue inflammation, typical of the reaction to a foreign body, followed by the corresponding local growth of fibrous connective tissue. This is followed by a gradual loss of suture strength and mass due to absorption by the hydrolysis process in which the suture is metabolized into adipic acid which is eventually absorbed and fully metabolized in the tissues. During the absorption of MONOFAST suture there is initially a loss of strength without significant loss of mass. The suture has a residual strength of 68-78% after one week and up to 30% towards the end of the second week. Absorption of the suture is completed within 90 to 110 days. All of the initial strength of the suture is lost within 28 days.